Zhengzhou University
Clinical trials sponsored by Zhengzhou University, explained in plain language.
-
New combo therapy aims to tackle rare brain cancer
Disease control Not yet recruitingThis study tests a combination of four treatments—a CAR-T cell therapy, a stem cell transplant, and two targeted drugs—for people with primary central nervous system lymphoma (PCNSL), a rare brain cancer. The goal is to see if this powerful mix can control the disease better than…
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated May 26, 2026 09:30 UTC
-
New combo therapy targets hard-to-treat lymphoma after standard drugs fail
Disease control Not yet recruitingThis study tests a combination of four drugs (zuberitamab, selinexor, dexamethasone, and thalidomide) in 30 adults aged 18-70 with mantle cell lymphoma that has returned or not responded after BTK inhibitor treatment. The goal is to improve remission rates and extend survival wit…
Phase: PHASE4 • Sponsor: Zhengzhou University • Aim: Disease control
Last updated May 26, 2026 09:28 UTC
-
New drug cocktail aims to fight rare lymphoma without chemo
Disease control Not yet recruitingThis study tests whether a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) can effectively treat marginal zone lymphoma in people who have not received prior therapy. About 50 adults aged 18-75 with advanced-stage disease will take the drugs and be monitore…
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated May 22, 2026 13:54 UTC